HSBC Innovation Banking’s Post

#UnionBudget2024 | #Pharma sector boosted with increased #R&D allocation, #digitalhealthcare promotion, and simplified compliance. Three #cancerdrugs exempt from #customduties, making treatments more accessible and affordable, driving sector growth: Vijay Chawla, KPMG India. #Budget2024 #KPMGBudgetLIVE

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharmaceuticals Inc. is ready to do deals. Catherine Owen Adams walks us through the latest on NUPLAZID and DAYBUE, and products in development for Alzheimer's psychosis, Prader-Willi, and essential tremor. Plus, the company's $700M cash balance and deal appetite. Full video: https://lnkd.in/gNDBJ7rk BiotechTV's coverage of SF Healthcare Week is brought to you by: HSBC Innovation Banking. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills

Fisdom On August 1st, the benchmark index Nifty reached a fresh all-time high of 25,080. The index rose by almost 4% in July. Nifty IT, Healthcare Index, and Pharma Index were the top gainers, outperforming the benchmark index. #Nifty50

What do investors need to know about GLP-1 drugs? Originally treatments for diabetes, they have the potential to transform not only global health, but global healthcare. Yann Mauron, Private Equity Investor at Pictet Alternative Advisors, analyses the implications and scope for disruption created by this phenomenal innovation: https://lnkd.in/dVwXJwTQ. #Pictet #Healthcare #PrivateEquity #Investors #Innovation

💊 Comprehensive overview of new Swiss healthcare regulations This latest blog post from PwC Switzerland is a must-read for anyone involved in the Swiss healthcare sector. Dive into the strategic guide crafted by our experts, Dr. Sandra Ragaz-Fumia and Dominik Hofstetter, detailing the latest regulatory changes. Learn about: ✅ New pricing mechanisms ✅ Adjustments in foreign price comparisons ✅ Early access for critical drugs ✅ Transparency enhancements ➡️ Stay informed and ahead of the curve with PwC. Discover the full insights here: https://pwc.to/3zJSALI #HealthcareRegulations #PharmaIndustry #SwissRegulations #PwCBlog #MarketAccess #DrugPricing #TransparencyInHealthcare

European #MandA #Deal making in Q3 2024 - Looking at the 𝗡𝗘𝗪 𝗡𝗢𝗥𝗠𝗔𝗟? After four consecutive quarters with bad news on the deals front, we have finally seen a strong rebound in both number of deals as well as overall valuation for the #MedTech sector. However, the levels we are seeing right now are still way behind figures of 8-10 quarters before. Also on the world of #Pharma and #Chemicals there is a least something like a floor or even slight upward trend to be observed. This is also reflected by many market participants who do confirm a certain uplift in number of deal opportunities as well as size of transactions. However, and most apparently driven by local regulatory and political movements, the #healthcare segment has suffered - again. Even though the #PrivateEquity scene is taking a more positive view to patient care and other core healthcare activities, there are still not many major deals to be recognized. Speaking to market participants we see a little silver lining on the horizon most likely to materialize in early 2025. Our current #FocusPiece provides some insights on value creation opportunities in the MedTech sector especially in light of full #MDR application but also other external factors. We take a look at which sub-segments might provide the highest promises and where to be rather selective. Enjoy our latest insights in our European M&A Industry Quarterly. https://lnkd.in/efqVvyMg

The equitable distribution of medicines and their accessibility are critical to the resilience of the healthcare system. However, disparities in access and equity continue to exist and these are pertinent to address, especially as healthcare disruptions can negatively impact an economy's public health and patient care.   In recent years, supply chain risk management practices have been revolutionised by technology, with new innovations and risk management solutions reducing accessibility concerns through real-time insights and data-driven mitigation strategies. Read this BioSpectrum Asia article to learn how Zuellig Pharma harnesses the transformative potential of disruptive technologies to enhance supply chain resilience, agility, and responsiveness to risks, developing a connected pharmaceutical ecosystem through innovative digital platforms: https://lnkd.in/d3T5TEWv   #HealthcareAccess #SupplyChainRiskManagement #HealthcareInnovation #Sustainability #ESG 

💊 Comprehensive overview of new Swiss healthcare regulations This latest blog post from PwC Switzerland is a must-read for anyone involved in the Swiss healthcare sector. Dive into the strategic guide crafted by our experts, Dr. Sandra Ragaz-Fumia and Dominik Hofstetter, detailing the latest regulatory changes. Learn about: ✅ New pricing mechanisms ✅ Adjustments in foreign price comparisons ✅ Early access for critical drugs ✅ Transparency enhancements ➡️ Stay informed and ahead of the curve with PwC. Discover the full insights here: https://pwc.to/3zJSALI #HealthcareRegulations #PharmaIndustry #SwissRegulations #PwCBlog #MarketAccess #DrugPricing #TransparencyInHealthcare

💊 Comprehensive overview of new Swiss healthcare regulations This latest blog post from PwC Switzerland is a must-read for anyone involved in the Swiss healthcare sector. Dive into the strategic guide crafted by our experts, Dr. Sandra Ragaz-Fumia and Dominik Hofstetter, detailing the latest regulatory changes. Learn about: ✅ New pricing mechanisms ✅ Adjustments in foreign price comparisons ✅ Early access for critical drugs ✅ Transparency enhancements ➡️ Stay informed and ahead of the curve with PwC. Discover the full insights here: https://pwc.to/3zJSALI #HealthcareRegulations #PharmaIndustry #SwissRegulations #PwCBlog #MarketAccess #DrugPricing #TransparencyInHealthcare

💊 Comprehensive overview of new Swiss healthcare regulations This latest blog post from PwC Switzerland is a must-read for anyone involved in the Swiss healthcare sector. Dive into the strategic guide crafted by our experts, Dr. Sandra Ragaz-Fumia and Dominik Hofstetter, detailing the latest regulatory changes. Learn about: ✅ New pricing mechanisms ✅ Adjustments in foreign price comparisons ✅ Early access for critical drugs ✅ Transparency enhancements ➡️ Stay informed and ahead of the curve with PwC. Discover the full insights here: https://pwc.to/3zJSALI #HealthcareRegulations #PharmaIndustry #SwissRegulations #PwCBlog #MarketAccess #DrugPricing #TransparencyInHealthcare